Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A., a foreign private issuer, covers the reporting period ending on April 3, 2026. The report serves to disseminate a press release dated April 3, 2026, to U.S. investors pursuant to Rule 13a-16 under the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document consists solely of the cover page and exhibit index for a press release, without including the financial data itself.
Material Changes
The filing text does not provide a clear value regarding material changes versus the prior comparable period. No comparative financial data or operational updates are included in the provided text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The content is limited to the administrative details of the report and the reference to an attached press release (Exhibit 99.1).
Investor Verification Checklist
- Verify the full content of the press release dated April 3, 2026, referenced as Exhibit 99.1, as the financial details are not in the cover text.
- Confirm the specific nature of the announcement (e.g., clinical trial results, partnership, or financial update) by accessing the attached exhibit.
- Review the company's most recent Form 20-F for baseline financial data to contextualize any new information in the press release.